Methods of Treating, Reducing the Incidence of, and/or Preventing Ischemic Events

Abstract

Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising bivalirudin or a P2Y 12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor, and optionally bivalirudin. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.

What is claimed is: 
     
         1 . A method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor and a pharmaceutical composition comprising bivalirudin. 
     
     
         2 . The method of  claim 1 , wherein the method treats, reduces the incidence of, or prevents an ischemic event during PCI. 
     
     
         3 . The method of  claim 1 , wherein the method treats, reduces the incidence of, or prevents an ischemic event after PCI. 
     
     
         4 . The method of  claim 1 , wherein the ischemic event is selected from the group consisting of stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality. 
     
     
         5 . The method of  claim 4 , wherein the ischemic event is stent thrombosis. 
     
     
         6 . The method of  claim 5 , wherein the stent thrombosis is intraprocedural stent thrombosis. 
     
     
         7 . The method of  claim 1 , wherein the pharmaceutical composition comprising cangrelor and the pharmaceutical composition comprising bivalirudin are administered to the patient before PCI, during PCI, after PCI, or a combination thereof. 
     
     
         8 . The method of  claim 1 , wherein the pharmaceutical composition comprising cangrelor and the pharmaceutical composition comprising bivalirudin are administered to the patient intravenously. 
     
     
         9 . The method of  claim 8 , wherein the pharmaceutical composition comprising cangrelor and the pharmaceutical composition comprising bivalirudin are administered as a bolus, as a continuous infusion, or as a bolus followed by a continuous infusion. 
     
     
         10 . The method of  claim 9 , wherein the bolus of the pharmaceutical composition comprising cangrelor is in a dose of about 20 μg/kg to about 40 μg/kg cangrelor. 
     
     
         11 . The method of  claim 10 , wherein the continuous infusion of the pharmaceutical composition comprising cangrelor is in a dose of about 1 μg/kg/min to about 10 μg/kg/min cangrelor. 
     
     
         12 . The method of  claim 9 , wherein the bolus of the pharmaceutical composition comprising bivalirudin is in a dose of about 0.1 mg/kg to about 10 mg/kg bivalirudin. 
     
     
         13 . The method of  claim 12 , wherein the continuous infusion of the pharmaceutical composition comprising bivalirudin is in a dose of about 0.5 mg/kg/hr to about 10 mg/kg/hr bivalirudin. 
     
     
         14 . The method of  claim 1 , wherein the administration of the pharmaceutical composition comprising cangrelor and the pharmaceutical composition comprising bivalirudin to the patient is not accompanied by a significant increase in severe bleeding or the need for transfusions. 
     
     
         15 . The method of  claim 1 , wherein the PCI comprises stent implantation. 
     
     
         16 . The method of  claim 1 , further comprising administering a P2Y 12  inhibitor selected from the group consisting of clopidogrel, prasugrel, and ticagrelor.